A Director at Haemonetics is Exercising Options
Yesterday it was reported that a Director at Haemonetics (HAE), Ronald Gelbman, exercised options to sell 16,926 HAE shares at $39.36 a share, for a total transaction value of $2M.
In addition to Ronald Gelbman, 2 other HAE executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Haemonetics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $253 million and quarterly net profit of $37.49 million. In comparison, last year the company earned revenue of $242 million and had a net profit of $18.73 million. The company has a one-year high of $140.36 and a one-year low of $80.24. Currently, Haemonetics has an average volume of 427.90K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other.